close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.840 +0.130 (+7.60%)
Official Closing Price Updated: 8:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
A Peek at Lineage Cell Therapeutics's Future Earnings
 
Via Benzinga
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
From Lineage Cell Therapeutics, Inc.
Via Business Wire
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
 
Via Benzinga
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Lineage Cell Revenue Doubles in Q2
Via The Motley Fool
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027. 
Via Chartmill
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Two Biotech Stocks Poised For Big Moves On Monday
 
Via Benzinga
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook
 
Via Benzinga
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For May 13, 2025
 
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today